Nexthera Capital Lp Buys UroGen Pharma, Amarin Corp PLC, Sarepta Therapeutics Inc, Sells Novartis AG, Heron Therapeutics Inc, Audentes Therapeutics Inc

• New Purchases: URGN, AMRN, SRPT, QURE, NBIX, ACOR, AGN, ICPT, KNSA, SAGE, BMRN, MDGL,
• Reduced Positions: NVS, HRTX, BOLD, BHC, IMMU, INSM, GBT, EXEL, CBAY, STML, CHMA, DCPH,
• Sold Out: HZNP, CBIO, ZSAN, ATNX, OSMT, MDWD, VCNX,

For the details of NEXTHERA CAPITAL LP's stock buys and sells, go to https://www.gurufocus.com/guru/nexthera+capital+lp/current-portfolio/portfolio

1. Audentes Therapeutics Inc (BOLD) - 250,620 shares, 11.87% of the total portfolio. Shares reduced by 67.2%
2. Heron Therapeutics Inc (HRTX) - 388,623 shares, 11.53% of the total portfolio. Shares reduced by 52.56%
3. Insmed Inc (INSM) - 284,263 shares, 10.03% of the total portfolio. Shares reduced by 66.12%
4. Immunomedics Inc (IMMU) - 334,724 shares, 7.80% of the total portfolio. Shares reduced by 62.59%
5. Bausch Health Companies Inc (BHC) - 205,660 shares, 6.16% of the total portfolio. Shares reduced by 69.07%

Nexthera Capital Lp initiated holding in UroGen Pharma Ltd. The purchase prices were between $35.47 and $54.55, with an estimated average price of $42.07. The stock is now traded at around $39.29. The impact to a portfolio due to this purchase was 5.94%. The holding were 132,589 shares as of .

Nexthera Capital Lp initiated holding in Amarin Corp PLC. The purchase prices were between $12.61 and $22.33, with an estimated average price of $17.95. The stock is now traded at around $16.92. The impact to a portfolio due to this purchase was 3.75%. The holding were 148,695 shares as of .

Nexthera Capital Lp initiated holding in Sarepta Therapeutics Inc. The purchase prices were between $106.67 and $151.68, with an estimated average price of $128.32. The stock is now traded at around $119.19. The impact to a portfolio due to this purchase was 3.08%. The holding were 21,270 shares as of .

Nexthera Capital Lp initiated holding in uniQure NV. The purchase prices were between $27.39 and $68.41, with an estimated average price of $44.1. The stock is now traded at around $58.51. The impact to a portfolio due to this purchase was 2.81%. The holding were 38,800 shares as of .

Nexthera Capital Lp initiated holding in Neurocrine Biosciences Inc. The purchase prices were between $69.31 and $91.53, with an estimated average price of $83.53. The stock is now traded at around $78.89. The impact to a portfolio due to this purchase was 2.57%. The holding were 24,040 shares as of .

Nexthera Capital Lp initiated holding in Acorda Therapeutics Inc. The purchase prices were between $12.93 and $17.47, with an estimated average price of $15.03. The stock is now traded at around $11.28. The impact to a portfolio due to this purchase was 2.5%. The holding were 154,806 shares as of .

Nexthera Capital Lp sold out a holding in Horizon Therapeutics PLC. The sale prices were between $19.49 and $29.01, with an estimated average price of $23.59.

Nexthera Capital Lp sold out a holding in Catalyst Biosciences Inc. The sale prices were between $7.67 and $9.96, with an estimated average price of $8.55.

Nexthera Capital Lp sold out a holding in Zosano Pharma Corp. The sale prices were between $2.12 and $6, with an estimated average price of $3.44.

Nexthera Capital Lp sold out a holding in Athenex Inc. The sale prices were between $11.11 and $13.49, with an estimated average price of $12.2.

Nexthera Capital Lp sold out a holding in Osmotica Pharmaceuticals PLC. The sale prices were between $3.6 and $8.75, with an estimated average price of $7.39.

Nexthera Capital Lp sold out a holding in MediWound Ltd. The sale prices were between $4.06 and $5.24, with an estimated average price of $4.79.